New 📰: Low Allele Frequency Variants Identified on Germline Multi-Gene Panel Testing for Cancer Predisposition Can Suggest the Presence of Constitutional Mosaicism 🔓pubmed.ncbi.nlm.nih.gov/40260637/ ✍️Adela Rodríguez Hernández Brittany Bychkovsky, MD judy garber

Looking forward to two engaging days of learning and discussion at the #HarvardBreastCancerCourse — covering the latest in diagnosis, treatment, and survivorship! Join us in Boston or online, July 17–18! Register here 👇

Gastrointestinal cancers are increasing in young people - listen to the podcast below about our review article to learn more! Dana-Farber's Young-Onset Colorectal Cancer Center Dana-Farber News Dana-Farber Thejus Jayakrishnan

👩‍🔬 Conoce a la Dra. Barbara Rivera, investigadora clave en tumores raros de ovario. Su trabajo en mecanismos moleculares busca mejorar diagnóstico y tratamiento.   🔗 [raretumorovary.net/es/quienes-som…] \#NRTO #TumoresRaros #Investigación

Dr. Guilherme Nader Marta (Guilherme Nader Marta) discussed #Immunotherapy in #TNBC, reviewing key questions after KEYNOTE-522: ❔Is the adjuvant phase truly necessary in pts with pCR? ❔Can we omit #anthracyclines from the chemo backbone? What is the ideal chemo partner? ❔What if

Despite clear guidelines, germline genetic testing remains underutilized in patients with metastatic breast cancer. In our new study published in JCO Precision Oncology, we evaluated >15,000 patients with metastatic breast cancer and found that fewer than half received germline

After CDK4/6 Inhibitors: Advancing Treatment for HR+HER2-negative Metastatic Breast Cancer— Mafalda Oliveira, Erica Mayer, and Shom Goel will address this topic in an educational session at #SABCS25 (December 9-12). brnw.ch/21wUjob Mafalda Oliveira Erica Mayer Shom Goel

Exercise in patients with metastatic prostate cancer: A comprehensive review cancertreatmentreviews.com/article/S0305-… Physical activity🏃 and structured exercise have been shown to significantly improve quality of life in #ProstateCancer (PC) patients, particularly by alleviating side effects

.Filipa Lynce, MD, FASCO 🇵🇹 🇺🇸, MD, FASCO, recently received the Advanced Clinical Research Award in Breast Cancer Research from Conquer Cancer, the ASCO Foundation. Lynce's work will focus on deciphering mechanisms of response to novel therapies in HER2 expressing stage III Inflammatory Breast Cancer, paving the

The EPIK-O trial tested a new combo therapy for tough-to-treat ovarian cancer without #BRCAmutations. While it didn’t show more benefit than chemo, researchers uncovered clues that could help personalize future treatments. #OvarianCancer #EPIKOtrial ascopubs.org/doi/10.1200/JC…

Pleased to share the results of our prospective observational decision-impact study in early-stage HR+/HER2− breast cancer (NCT03749421). 🔗sciencedirect.com/science/articl… 🧵👇

Great work, Chiara! Grateful to kick off this project and, as always, learn alongside Sara Tolaney and Nancy Lin, MD. Personalized care is the future — every patient deserves a tailored approach. Thank you Sara, Nancy and Chiara. Dana-Farber’s Breast Oncology Center 🤓🔬

A phase I study of the CSF1R inhibitor vimseltinib in combination with the PD-L1 inhibitor avelumab in patients with advanced sarcoma in ESMO Open. No objective responses observed, CBR 16% in pts treated at RP2D. Therapy reduces MDSCs & regulatory T cells.esmoopen.com/article/S2059-…

Teresa Macarulla Carlos Fernandez de Larrea IDIBAPS Universitat de Barcelona Meritxell Mollà 🏥 Nombrados nuevos jefes de los servicios de Hematología y Oncología Médica del #CLÍNIC para potenciar el desarrollo asistencial y científico del Cancer Center. La Dra. Teresa Macarulla y el Dr. Carlos Fernandez de Larrea serán los futuros jefes de los Servicios de Oncología Médica y

Genetic testing for BRCA1/2 variants in Northern African women with ovarian and breast cancers: a multicentre study of an under-represented ancestry in ESMO Open. Unique BRCA1/2 variation patterns; 45/85 VUS, affecting 60% of pts, were reclassified. esmoopen.com/article/S2059-…

Today was my 4th #pmc2025. I rode 25 miles for my patients, their families and the important cancer research that we do at DFCI. Thank you all for your support. If you would like to donate, my PMC page is at: profile.pmc.org/BB0361

PARP inhibitors comprise a therapeutic class that targets PARP proteins involved in DNA repair. This #OpenAccess review of PARP inhibitor approvals emphasizes their efficacy across different cancers based on landmark phase 3 clinical trials. 🔗: acsjournals.onlinelibrary.wiley.com/doi/full/10.33…

Congratulations to Dr. Elia Segui (Elia Seguí, MD) on receiving the Basic Science/Pre-Clinical Award at the 2025 SNO/ASCO CNS Metastases Conference! 💫 SNO ASCO #CNSMetastases #SNOASCO2025 #CNS #BrainMets

Genetic and Epigenetic Determinants of BRCA1/2 Tumorigenesis: Joan Brugge will address this topic in a plenary lecture at #SABCS25 (December 9-12). Learn more: brnw.ch/21wV2bK JOAN BRUGGE

¿Eres oncólogo médico interesado en cáncer urológico? Quizás te interesa trabajar y desarrollar tu carrera con nosotros en el Hospital Clínic . Escríbeme y comentamos los detalles